Aliases & Classifications for Stomatitis

MalaCards integrated aliases for Stomatitis:

Name: Stomatitis 12 75 55 44 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9637
MeSH 44 D013280
NCIt 50 C26887
SNOMED-CT 68 61170000 95361005
ICD10 33 K12.1
UMLS 72 C0038362

Summaries for Stomatitis

MalaCards based summary : Stomatitis is related to measles and ebola hemorrhagic fever, and has symptoms including enanthema, oral mucosal blisters and oral manifestations. An important gene associated with Stomatitis is LDLR (Low Density Lipoprotein Receptor), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Morphine and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include breast, t cells and lung, and related phenotypes are Decreased cell number and Decreased cell number

Wikipedia : 75 Stomatitis is inflammation of the mouth and lips. It refers to any inflammatory process affecting the... more...

Related Diseases for Stomatitis

Diseases related to Stomatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 507)
# Related Disease Score Top Affiliating Genes
1 measles 30.9 EIF2AK2 DDX58 ADAR
2 ebola hemorrhagic fever 30.8 DDX58 BST2
3 chikungunya 30.6 RSAD2 DDX58 BST2
4 influenza 30.2 RSAD2 IFITM3 IFITM2 EIF2AK2 DDX58
5 dengue virus 30.0 RSAD2 IFITM3 IFITM2 DDX58
6 west nile virus 30.0 RSAD2 IFITM3 IFITM2 DDX58
7 hepatitis c 29.8 LDLR IFNA2 EIF2AK2 DDX58
8 hepatitis c virus 29.7 RSAD2 LDLR HNRNPK EIF2AK2 DDX58 BST2
9 viral infectious disease 29.5 IFNA2 EIF2AK2 DDX58
10 felty syndrome 28.9 CSF3 CSF2
11 aphthous stomatitis 12.7
12 periodic fever, aphthous stomatitis, pharyngitis and adenitis 12.7
13 denture stomatitis 12.6
14 ulcerative stomatitis 12.6
15 sutton disease 2 12.2
16 noma 11.8
17 hand, foot and mouth disease 11.7
18 ariboflavinosis 11.5
19 glucagonoma 11.5
20 angular cheilitis 11.5
21 necrotizing ulcerative gingivitis 11.5
22 methylmalonic aciduria and homocystinuria, cblf type 11.2
23 oral candidiasis 10.9
24 pharyngitis 10.7
25 cervical adenitis 10.6
26 vaccinia 10.5
27 mouth disease 10.5
28 herpes simplex 10.5
29 mucositis 10.5
30 gingivitis 10.5
31 rabies 10.5
32 lichen planus 10.5
33 helix syndrome 10.5
34 candidiasis 10.4
35 glossitis 10.4
36 human immunodeficiency virus type 1 10.4
37 newcastle disease 10.4
38 dermatitis 10.4
39 encephalitis 10.4
40 oral lichen planus 10.4
41 exanthem 10.3
42 neutropenia 10.3
43 cheilitis 10.3
44 periodontitis 10.3
45 celiac disease 1 10.3
46 allergic hypersensitivity disease 10.3
47 hair whorl 10.2
48 tonsillitis 10.2
49 conjunctivitis 10.2
50 uvulitis 10.2

Graphical network of the top 20 diseases related to Stomatitis:



Diseases related to Stomatitis

Symptoms & Phenotypes for Stomatitis

UMLS symptoms related to Stomatitis:


enanthema, oral mucosal blisters, oral manifestations, burning mucosal, oral pain, sore roof of mouth (symptom)

GenomeRNAi Phenotypes related to Stomatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell number GR00098-A-1 9.17 EIF3I HNRNPK UBA52
2 Decreased cell number GR00303-A 9.17 EIF3I HNRNPK NUP98 UBA52

MGI Mouse Phenotypes related to Stomatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.36 ADAR ATG5 CSF2 CSF3 DDX58 EIF2AK2

Drugs & Therapeutics for Stomatitis

Drugs for Stomatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 388)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4 57-27-2 5288826
2
Ethanol Approved Phase 4 64-17-5 702
3
Racepinephrine Approved Phase 4 329-65-7 838
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Hexetidine Approved, Investigational Phase 4 141-94-6
7
Cefpirome Approved Phase 4 84957-29-9 5479539
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Promethazine Approved, Investigational Phase 4 60-87-7 4927
14
Histamine Approved, Investigational Phase 4 51-45-6 774
15
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
16
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
19
Simethicone Approved Phase 4 8050-81-5
20
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
21
Povidone Approved Phase 4 9003-39-8
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
23
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
24
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
25
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
26
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
27
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
28 Ionophores Phase 4
29 Anti-Infective Agents, Local Phase 4
30 Disinfectants Phase 4
31 Sodium hypochlorite Phase 4
32 Chlorhexidine gluconate Phase 4
33 Eusol Phase 4
34 Castor Phase 4
35 Epinephryl borate Phase 4
36 Citrate Phase 4
37 Ether Phase 4
38 N-Methylaspartate Phase 4
39 alanine Phase 4
40
Bilirubin Phase 4 635-65-4, 69853-43-6 5280352 21252250
41 Contraceptives, Oral Phase 4
42 Contraceptive Agents Phase 4
43 Contraceptives, Oral, Combined Phase 4
44 Norgestimate, ethinyl estradiol drug combination Phase 4
45 Cephalosporins Phase 4
46 Estradiol 3-benzoate Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Gastrointestinal Agents Phase 4
49 Central Nervous System Depressants Phase 4
50 Anesthetics, Local Phase 4

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
2 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
3 Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash;Placebo
4 Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers: a Randomized Clinical Trial Completed NCT02642900 Phase 4 Nystatin 100.000 units
5 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
6 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
7 Clinical Evaluation of an Experimental Solution Based on Ricinus Communis Compared to Sodium Hypochlorite for Denture Cleansing Completed NCT02407834 Phase 4
8 Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
9 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
10 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
11 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
12 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT01707641 Phase 4
13 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
14 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
15 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
16 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
17 The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial Unknown status NCT01083420 Phase 3 Minocycline;Dexamethasone
18 Evaluation of Oral Care to Prevent Oral Mucositis in Estrogen Receptor Positive Metastatic Breast Cancer Patients Treated With Everolimus: Phase III Randomized Control Trial Unknown status NCT02376985 Phase 3 Everolimus
19 A Randomized, Double-Blind, Placebo-Controlled Pilot Study for Evaluating the Efficacy of the Homeopathic Remedy Traumeel S on Pain Reduction Following Tonsillectomy in Adult Patients. Unknown status NCT00410332 Phase 3 Traumeel S;Placebo
20 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
21 Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1" Unknown status NCT01007617 Phase 2, Phase 3
22 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People Completed NCT02818803 Phase 3 Miconazole
23 Prevention of Recurrent Aphthous Stomatitis Using Vitamins Completed NCT00527306 Phase 3
24 Effect of Low-level Laser Therapy on Inflammatory Mediators Release During Chemotherapy-induced Oral Mucositis: a Randomized Preliminary Study Completed NCT02050373 Phase 3
25 A Randomized,Controlled Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis. Completed NCT02303197 Phase 3 ChiNing decoction
26 Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan Completed NCT01837446 Phase 2, Phase 3 2% morphine solution;Magnesium aluminum hydroxide;2% viscous lidocaine;Diphenhydramine
27 A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine HCl 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Mucositis Completed NCT00051441 Phase 3 Benzydamine Hydrochloride 0.15% Oral Rinse
28 LAMPO: Multicenter Randomized Double-blind Controlled Trial to Evaluate the Efficacy of Laser Therapy for Treatment of Oral Mucositis Induced by Chemotherapy in Children Completed NCT02762019 Phase 3
29 A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Recombinant Human Keratinocyte Growth Factor for Reduction of Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy With Autologous PBPC Transplantation Completed NCT00041665 Phase 3 Recombinant Human Keratinocyte Growth Factor
30 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
31 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Assess the Efficacy and Safety of SBG on Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT00790322 Phase 3 SBG
32 A Randomized, Blinded, Active-control Trial of Palifermin (rHuKGF) to Evaluate Oral Mucositis in Subjects With Hematologic Malignancies Undergoing Fractionated Total Body Irradiation (fTBI) and High Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation Completed NCT00109031 Phase 3 palifermin;Cyclophosphamide;Etoposide;Placebo
33 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT) Completed NCT00101582 Phase 3 Placebo;palifermin;cisplatin chemotherapy
34 [rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone Completed NCT02378753 Phase 2, Phase 3
35 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy(RT/CT) Completed NCT00131638 Phase 3 Placebo;Palifermin
36 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer Receiving 5-FU and Leucovorin as Adjuvant Therapy Completed NCT00393822 Phase 2, Phase 3 palifermin;placebo
37 Evaluate Safety and Tolerability and Compare Absorption/Distribution Kinetics of a Single 100 Mcg Dose of Fentanyl Sublingual Spray (Fentanyl SL Spray) in Cancer Subjects With or Without Oral Mucositis Completed NCT00956254 Phase 3 Fentanyl sublingual spray
38 Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation Completed NCT01439724 Phase 3
39 Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens Completed NCT00822393 Phase 3 Busulfan;Treosulfan
40 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer Completed NCT00615420 Phase 3
41 Khon Kaen University Ethics Committee in Human Research Completed NCT02536781 Phase 2, Phase 3 Anthocyanin;Placebo
42 A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation Completed NCT00434161 Phase 3 Palifermin before only;Placebo;Palifermin before and after
43 Effect of Ascorbic Acid Oral Supplementation in Assessing the Severity of Oral Mucositis in Chemo-radiation Therapy of Head and Neck Cancers. Completed NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
44 Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy Completed NCT01265810 Phase 3
45 Randomized Cross-over Study of Curcumin for Prevention of Oral Mucositis in Children Receiving Doxorubicin Based Chemotherapy. Completed NCT00475683 Phase 3
46 A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3 doxepin hydrochloride oral solution;DLA (diphenhydramine, lidocaine and antacids) rinse
47 A Comparison of Acute Oral Mucositis Between Morning and Afternoon Radiotherapy in Patients Receiving Radiation Treatment for Cancer of the Head and Neck Completed NCT00004234 Phase 3
48 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
49 A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease Completed NCT00445432 Phase 2, Phase 3
50 Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial Completed NCT02555501 Phase 3

Search NIH Clinical Center for Stomatitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


carbamide peroxide
Diphenhydramine
Dyclonine
Palifermin
Sucralfate
Triamcinolone

Cochrane evidence based reviews: stomatitis

Genetic Tests for Stomatitis

Anatomical Context for Stomatitis

MalaCards organs/tissues related to Stomatitis:

41
Breast, T Cells, Lung, Bone, Testes, Kidney, Bone Marrow

Publications for Stomatitis

Articles related to Stomatitis:

(show top 50) (show all 14118)
# Title Authors PMID Year
1
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. 9 38
17520255 2008
2
DPYD*2A mutation: the most common mutation associated with DPD deficiency. 9 38
17165084 2007
3
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. 9 38
17409804 2007
4
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. 9 38
15550581 2004
5
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. 9 38
15539918 2004
6
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. 9 38
12352929 2002
7
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. 9 38
10473079 1999
8
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. 9 38
9007910 1997
9
High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. 9 38
7524888 1994
10
Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. 38
30972741 2019
11
Expression and characterization of albumin fusion protein canine IFNγ-CSA in baculovirus-insect cell expression system. 38
31100416 2019
12
GNAQ Negatively Regulates Antiviral Innate Immune Responses in a Calcineurin-Dependent Manner. 38
31324725 2019
13
Recurrent aphthous stomatitis - Etiology, serum autoantibodies, anemia, hematinic deficiencies, and management. 38
30446298 2019
14
Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance. 38
31312717 2019
15
Rare missense variants in the ALPK1 gene may predispose to periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. 38
31053777 2019
16
Seventeen New Cases of Chronic Ulcerative Stomatitis with Literature Review. 38
30374883 2019
17
Eugenol allergy mimicking recurrent aphthous stomatitis and burning mouth syndrome. 38
31373017 2019
18
The alpha-1 subunit of the Na+,K+-ATPase (ATP1A1) is required for macropinocytic entry of respiratory syncytial virus (RSV) in human respiratory epithelial cells. 38
31381610 2019
19
BODIPY-embedded electrospun materials in antimicrobial photodynamic inactivation. 38
31147667 2019
20
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. 38
31040252 2019
21
Risk factors associated with extraintestinal manifestations in children with inflammatory bowel disease. 38
31395971 2019
22
Schlafen 11 Restricts Flavivirus Replication. 38
31118262 2019
23
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV). 38
31375575 2019
24
Nicotine Upregulates Coaggregation of Candida albicans and Streptococcus mutans. 38
28598524 2019
25
Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. 38
30953238 2019
26
Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer. 38
31415934 2019
27
SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis. 38
31092575 2019
28
Recombinant Vesicular Stomatitis Virus Vector Vaccines for WHO Blueprint Priority Pathogens. 38
31368826 2019
29
Reversible Gene Regulation in Mammalian Cells Using Riboswitch-Engineered Vesicular Stomatitis Virus Vector. 38
31415142 2019
30
Doxycycline: An option in the treatment of ulcerated oral lesions? 38
31400293 2019
31
Clinical features and new diagnostic criteria for the syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis. 38
31131563 2019
32
Effectiveness of booster dose of tetanus and diphtheria toxoids (Td) vaccine in management of recurrent aphthous stomatitis: A prospective, randomized, triple-blind and placebo-controlled clinical trial. 38
31403361 2019
33
Improving Baculovirus Transduction of Mammalian Cells by Incorporation of Thogotovirus Glycoproteins. 38
31201733 2019
34
Detection of neural connections with ex vivo MRI using a ferritin-encoding trans-synaptic virus. 38
31022567 2019
35
Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge. 38
31153968 2019
36
R7A mutation in N protein renders temperature sensitive phenotype of VSV by affecting its replication and transcription in vitro. 38
31093844 2019
37
Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies. 38
31410657 2019
38
Effect of Lozenges Containing Lactobacillus reuteri on the Severity of Recurrent Aphthous Ulcers: a Pilot Study. 38
31410765 2019
39
Towards better diagnostic criteria for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome. 38
30901126 2019
40
Melittin: a venom-derived peptide with promising anti-viral properties. 38
31422545 2019
41
Essentials of recurrent aphthous stomatitis. 38
31384457 2019
42
Evaluating Temperature Sensitivity of Vesicular Stomatitis Virus-Based Vaccines. 38
31141474 2019
43
A novel prognostic biomarker for recurrent aphthous stomatitis: calprotectin. 38
31284886 2019
44
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production. 38
30741586 2019
45
IL-27 posttranslationally regulates Y-box binding protein-1 to inhibit HIV-1 replication in human CD4+ T cells. 38
31274540 2019
46
Factors Associated with Untreated Decayed Teeth in Male Sales Workers: An Internet Survey. 38
31308308 2019
47
New therapeutic targeting of Alzheimer's disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response - preliminary study. 38
31277647 2019
48
Development of suspension adapted Vero cell culture process technology for production of viral vaccines. 38
31288997 2019
49
The autophagy protein ATG9A promotes HIV-1 infectivity. 38
31269971 2019
50
Performance of recently proposed periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome criteria in a region endemic for familial Mediterranean fever. 38
31346686 2019

Variations for Stomatitis

Expression for Stomatitis

Search GEO for disease gene expression data for Stomatitis.

Pathways for Stomatitis

Pathways related to Stomatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 UBA52 RSAD2 NUP98 IFNA2 IFITM3 IFITM2
2
Show member pathways
12.84 UBA52 RSAD2 NUP98 IFNA2 IFITM3 IFITM2
3
Show member pathways
12.51 UBA52 IFNA2 DDX58 ATG5 ATG12 ADAR
4
Show member pathways
12.01 RSAD2 IFNA2 IFITM3 IFITM2 BST2 ADAR
5
Show member pathways
11.81 UBA52 RSAD2 NUP98 IFNA2 IFITM3 IFITM2
6 11.64 IFNA2 CSF3 CSF2
7
Show member pathways
10.82 IFNA2 EIF2AK2 DDX58 ADAR

GO Terms for Stomatitis

Cellular components related to Stomatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phagophore assembly site membrane GO:0034045 8.96 ATG5 ATG12
2 Atg12-Atg5-Atg16 complex GO:0034274 8.62 ATG5 ATG12

Biological processes related to Stomatitis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.95 RSAD2 IFITM3 IFITM2 EIF2AK2 DDX58 BST2
2 immune system process GO:0002376 9.93 RSAD2 EIF2AK2 DDX58 ATG5 ADAR
3 viral process GO:0016032 9.93 RSAD2 NUP98 LDLR HNRNPK EIF2AK2 DDX58
4 negative regulation of apoptotic process GO:0043066 9.92 UBA52 HNRNPK EIF2AK2 ATG5 ADAR
5 cytokine-mediated signaling pathway GO:0019221 9.81 UBA52 IFNA2 CSF3 CSF2
6 type I interferon signaling pathway GO:0060337 9.73 RSAD2 IFNA2 IFITM3 IFITM2 BST2 ADAR
7 negative regulation of viral genome replication GO:0045071 9.72 RSAD2 IFITM3 IFITM2 EIF2AK2 BST2
8 response to virus GO:0009615 9.7 RSAD2 IFITM3 IFITM2 EIF2AK2 DDX58 BST2
9 response to interferon-gamma GO:0034341 9.65 IFITM3 IFITM2 BST2
10 negative regulation of viral entry into host cell GO:0046597 9.61 IFNA2 IFITM3 IFITM2
11 defense response to virus GO:0051607 9.56 RSAD2 IFNA2 IFITM3 IFITM2 EIF2AK2 DDX58
12 response to interferon-beta GO:0035456 9.54 IFITM3 IFITM2 BST2
13 C-terminal protein lipidation GO:0006501 9.49 ATG5 ATG12
14 response to interferon-alpha GO:0035455 9.02 IFITM3 IFITM2 EIF2AK2 BST2 ADAR

Molecular functions related to Stomatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 UBA52 TP63 RSAD2 NUP98 LDLR IFNA2
2 identical protein binding GO:0042802 9.73 TP63 LDLR HNRNPK EIF2AK2 DDX58 BST2
3 double-stranded RNA binding GO:0003725 9.33 EIF2AK2 DDX58 ADAR
4 Atg8 ligase activity GO:0019776 8.62 ATG5 ATG12

Sources for Stomatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....